Atea Q1 2024 net loss $63.2M; Phase 3 COVID trial enrollment complete, results due 2H 2024

Atea Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.75

Net loss $63.2M ($0.75 per share) vs $35.5M ($0.43) in Q1 2023.
R&D expense nearly doubled to $57.6M, driven by Phase 3 SUNRISE-3 and Phase 2 HCV trials.
Cash, equivalents, and marketable securities $541.5M, down $36.6M from year-end 2023.
Phase 3 COVID trial fully enrolled (2,221 patients in monotherapy cohort); topline results expected 2H 2024.
Phase 2 HCV lead-in cohort confirmed 98% SVR4; full Phase 2 results expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for three months ended March 31, 2024.

Period: three months ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Atea Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-138249

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.